Compile Data Set for Download or QSAR
Report error Found 50 Enz. Inhib. hit(s) with all data for entry = 2821
TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381830(US10272087, Compound 13 | US10272087, Compound 2)
Affinity DataIC50: 3.16nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381830(US10272087, Compound 13 | US10272087, Compound 2)
Affinity DataIC50: 3.16nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381830(US10272087, Compound 13 | US10272087, Compound 2)
Affinity DataIC50: 3.16nMAssay Description:In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381830(US10272087, Compound 13 | US10272087, Compound 2)
Affinity DataIC50: 3.98nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381830(US10272087, Compound 13 | US10272087, Compound 2)
Affinity DataIC50: 3.98nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381830(US10272087, Compound 13 | US10272087, Compound 2)
Affinity DataIC50: 3.98nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381830(US10272087, Compound 13 | US10272087, Compound 2)
Affinity DataIC50: 7.94nMAssay Description:In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381830(US10272087, Compound 13 | US10272087, Compound 2)
Affinity DataIC50: 7.94nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381829(US10272087, Compound 11 | US10272087, Compound 1)
Affinity DataIC50: 7.94nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381829(US10272087, Compound 11 | US10272087, Compound 1)
Affinity DataIC50: 10nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381834(US10272087, Compound 8)
Affinity DataIC50: 10nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381834(US10272087, Compound 8)
Affinity DataIC50: 25.1nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381835(US10272087, Compound 9)
Affinity DataIC50: 25.1nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381835(US10272087, Compound 9)
Affinity DataIC50: 25.1nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381834(US10272087, Compound 8)
Affinity DataIC50: 25.1nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 1/2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381830(US10272087, Compound 13 | US10272087, Compound 2)
Affinity DataIC50: 25.1nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381831(US10272087, Compound 3)
Affinity DataIC50: 25.1nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381831(US10272087, Compound 3)
Affinity DataIC50: 31.6nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381835(US10272087, Compound 9)
Affinity DataIC50: 31.6nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381829(US10272087, Compound 11 | US10272087, Compound 1)
Affinity DataIC50: 39.8nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381833(US10272087, Compound 7)
Affinity DataIC50: 39.8nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381834(US10272087, Compound 8)
Affinity DataIC50: 39.8nMAssay Description:In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381833(US10272087, Compound 7)
Affinity DataIC50: 50.1nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381835(US10272087, Compound 9)
Affinity DataIC50: 79.4nMAssay Description:In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381832(US10272087, Compound 4)
Affinity DataIC50: 79.4nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381831(US10272087, Compound 3)
Affinity DataIC50: 79.4nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381832(US10272087, Compound 4)
Affinity DataIC50: 100nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381831(US10272087, Compound 3)
Affinity DataIC50: 100nMAssay Description:In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381829(US10272087, Compound 11 | US10272087, Compound 1)
Affinity DataIC50: 100nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 1/2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381829(US10272087, Compound 11 | US10272087, Compound 1)
Affinity DataIC50: 100nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381829(US10272087, Compound 11 | US10272087, Compound 1)
Affinity DataIC50: 100nMAssay Description:In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381836(US10272087, Compound 10)
Affinity DataIC50: 126nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381833(US10272087, Compound 7)
Affinity DataIC50: 126nMAssay Description:In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381832(US10272087, Compound 4)
Affinity DataIC50: 158nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381836(US10272087, Compound 10)
Affinity DataIC50: 158nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381833(US10272087, Compound 7)
Affinity DataIC50: 158nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381836(US10272087, Compound 10)
Affinity DataIC50: 200nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381829(US10272087, Compound 11 | US10272087, Compound 1)
Affinity DataIC50: 200nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 1/2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381830(US10272087, Compound 13 | US10272087, Compound 2)
Affinity DataIC50: 251nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381829(US10272087, Compound 11 | US10272087, Compound 1)
Affinity DataIC50: 316nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381829(US10272087, Compound 11 | US10272087, Compound 1)
Affinity DataIC50: 316nMAssay Description:In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381832(US10272087, Compound 4)
Affinity DataIC50: 316nMAssay Description:In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 1/2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381835(US10272087, Compound 9)
Affinity DataIC50: 398nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381836(US10272087, Compound 10)
Affinity DataIC50: 501nMAssay Description:In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 1/2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381834(US10272087, Compound 8)
Affinity DataIC50: 794nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 1/2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381836(US10272087, Compound 10)
Affinity DataIC50: 1.00E+3nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 1/2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381831(US10272087, Compound 3)
Affinity DataIC50: 1.00E+3nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 1/2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381829(US10272087, Compound 11 | US10272087, Compound 1)
Affinity DataIC50: 1.00E+3nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 1/2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381833(US10272087, Compound 7)
Affinity DataIC50: 1.00E+3nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 1/2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM381832(US10272087, Compound 4)
Affinity DataIC50: 1.00E+3nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2020
Entry Details
Go to US Patent